Results 81 to 90 of about 3,260 (169)

Management of Adult Patients with Immune Thrombocytopenia (ITP): A Review on Current Guidance and Experience from Clinical Practice

Journal of Blood Medicine, 2021
Fei Song,1,2 Hanny Al-Samkari2,3 1Department of Medicine, Massachusetts General Hospital, Boston, MA, USA; 2Harvard Medical School, Boston, MA, USA; 3Division of Hematology, Massachusetts General Hospital, Boston, MA, USACorrespondence: Hanny Al ...
Song F, Al-Samkari H
doaj  

Immune thrombocytopenia secondary to primary cytomegalovirus infection after renal transplantation treated with a thrombopoietin receptor agonist: a case report. [PDF]

BMC Nephrol, 2023
Takehara T, Nishida H, Ichikawa K, Hosokawa Y, Nawano T, Takai S, Fukuhara H, Himuro M, Tsuchiya N, Watanabe M.   +9 more
europepmc   +1 more source

An Uncommon Association: Eltrombopag and Autoimmune Hepatitis

Case Reports in Hepatology
Autoimmune hepatitis (AIH) is an immunological disorder of the liver characterized by hepatic necroinflammation due to the break in self-tolerance to autoantigens. Many medications have been linked to drug induced AIH.
Fady Salama, Hassnain Syed, Nimish Thakral   +2 more
doaj   +1 more source

Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory/relapsed/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial. [PDF]

Ann Med, 2023
Wan Z, Chen M, Han B.
europepmc   +1 more source

Cerebral venous sinus thrombosis in immune thrombocytopenia patients treated with thrombopoietin receptor agonist: Case reports and literature review. [PDF]

Ann Med Surg (Lond), 2022
Teekaput C, Nadsasarn A, Tanprawate S, Soontornpun A, Thiankhaw K, Wantaneeyawong C, Teekaput K, Chai-Adisaksopha C.   +7 more
europepmc   +1 more source

Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia. [PDF]

Sci Rep, 2021
Lozano ML, Mingot-Castellano ME, Perera MM, Jarque I, Campos-Alvarez RM, González-López TJ, Carreño-Tarragona G, Bermejo N, Lopez-Fernandez MF, de Andrés A, Valcarcel D, Casado-Montero LF, Alvarez-Roman MT, Orts MI, Novelli S, Revilla N, González-Porras JR, Bolaños E, Rodríguez-López MA, Orna-Montero E, Vicente V.   +20 more
europepmc   +1 more source

Asymptomatic thrombocytopenia after nintedanib initiation in a patient with progressive pulmonary fibrosis: a case report and review of literature

Journal of Medical Case Reports
Background Nintedanib is a primary antifibrosing medication available for idiopathic pulmonary fibrosis, systemic sclerosis-interstitial lung disease, and progressive pulmonary fibrosis, with scattered report of drug-induced thrombocytopenia. Case report
Xinxin Zhang, Kan Zhang, Nannan Zhao, Na Xi, Tiemei Zhao   +4 more
doaj   +1 more source

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. [PDF]

J Hematol Oncol, 2021
Mei H, Liu X, Li Y, Zhou H, Feng Y, Gao G, Cheng P, Huang R, Yang L, Hu J, Hou M, Yao Y, Liu L, Wang Y, Wu D, Zhang L, Zheng C, Shen X, Hu Q, Liu J, Jin J, Luo J, Zeng Y, Gao S, Zhang X, Zhou X, Shi Q, Xia R, Xie X, Jiang Z, Gao L, Bai Y, Li Y, Xiong J, Li R, Zou J, Niu T, Yang R, Hu Y.   +38 more
europepmc   +1 more source

When Platelet Stimulation Becomes Marrow Stress: Rethinking Thrombopoietin Receptor Agonist Intensification in Pediatric Immune Thrombocytopenia. [PDF]

Pediatr Rep
Aricò M.
europepmc   +1 more source

Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters. [PDF]

Eur J Clin Pharmacol, 2020
Katsube T, Inoue Y, Fukuhara T, Kano T, Wajima T.   +4 more
europepmc   +1 more source